ASND
Ascendis A/SFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful clinical readouts, clear regulatory paths, or a strategic partnership could drive material re-rating; commercial execution on approved programs would further de-risk the story.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Clinical trial failure or negative readout
Momentum
67
Value
48
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.16 · Bull $46.08 · Bear $12.80
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-02 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $299.35
Why
Momentum67 · Δ7d -1.1
Value48 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
67
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
+11.1
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 67.0 / Value 48.5 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$15.7B
Beta
0.43
Shares Out
62.11M
P/E (TTM) · Derived
-59.5
P/S (TTM)
17.35
P/FCF (TTM) · Derived
302.87
Rev YoY
+171.5%
EPS YoY
-819.4%
Gross Margin
+87.4%
Op Margin
-22.5%
Net Debt
$300.36M
Current Ratio
1.00
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology